What type of study is this?

This is a Pre-Registered Trial study (also classified as: Human Clinical Trial, Experimental Study).

October 16, 2025CarcinogenesisOpen Access

Polo-like Kinase 4 (PLK4) as a Therapeutic Target in Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

APArmen ParsyanWestern University HAHarjot AthwalWestern University VBVasudeva BhatWestern University

Discussion

Member takes

Implication

This research uncovers the potential of PLK4 inhibition to reduce tumor growth and improve outcomes in breast cancer, indicating its role as a promising biomarker.

Key Points

Inhibition of PLK4 led to decreased cancer cell proliferation and increased cell death in preclinical models.
High PLK4 expression correlates with poor outcomes and aggressive breast cancer phenotypes in patients.
Therapeutic targeting of PLK4 enhances treatment efficacy, particularly in combination with radiotherapy.
PLK4 serves as a vital biomarker for prognosis and risk stratification in breast cancer patients.

Cite This Study

Parsyan et al. (2025) studied this question.

synapsesocial.com/papers/68f147cc724575985c3fd28a https://doi.org/10.1093/carcin/bgaf067

View Full Paper

Ask AI

Bookmark

Implication

This research uncovers the potential of PLK4 inhibition to reduce tumor growth and improve outcomes in breast cancer, indicating its role as a promising biomarker.

Polo-like Kinase 4 (PLK4) as a Therapeutic Target in Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Polo-like Kinase 4 (PLK4) as a Therapeutic Target in Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider